CELSET Introduces SOLTOX Botulinum Toxin Type A to International Markets

South Korean biotechnology company CELSET INC. has introduced SOLTOX, its brand of botulinum toxin type A, to the international medical aesthetics sector. The product is available in 100-unit and 200-unit formulations.

Technical Specifications and Manufacturing

According to the company, SOLTOX features three core technical characteristics:

• A toxin complex with a molecular weight of 900 kDa, including associated proteins.
• A lyophilized (freeze-dried) drug formulation intended for reconstitution before administration.
• An advanced purification process designed to separate the desired substance from undesired components.

CELSET emphasizes that the 900 kDa molecular size refers strictly to the structural property of the protein complex and does not constitute a claim of longer clinical duration or higher efficacy. The manufacturing approach incorporates controlled production conditions, filling, lyophilization, and batch evaluation procedures.

Market Presence and Verification

The introduction of SOLTOX expands CELSET's aesthetic medicine portfolio and highlights the growing global visibility of South Korean biotechnology manufacturing. The company states that market development and professional relationships are integral to the brand's international presence.

• Availability: Product availability and clinical use are governed by local regulatory requirements and product labeling in each country.
• Administration: Reconstitution and administration must be performed exclusively by qualified healthcare professionals.
• Verification: Interested parties can review official company information through the CELSET aesthetics homepage or contact corporate representatives directly via official communication channels.